Register entry

Lilly del Caribe, Inc.

Registered sites
0
Drug products
46
Live patents
0
Countries
0
Base
Unknown
Sites

Facilities

0

No registered facilities

This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.

Catalogue

Marketed products

46

Showing 46 of 46.

BrandGeneric nameFormCategory
-Atomoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Atomoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Atomoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Atomoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Atomoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Atomoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Atomoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Duloxetine hydrochlorideCAPSULE, DELAYED RELEASEDRUG FOR FURTHER PROCESSING
-Duloxetine hydrochlorideCAPSULE, DELAYED RELEASEDRUG FOR FURTHER PROCESSING
-Duloxetine hydrochlorideCAPSULE, DELAYED RELEASEDRUG FOR FURTHER PROCESSING
-Duloxetine hydrochlorideCAPSULE, DELAYED RELEASEDRUG FOR FURTHER PROCESSING
-Duloxetine hydrochlorideCAPSULE, DELAYED RELEASEDRUG FOR FURTHER PROCESSING
-Duloxetine hydrochlorideCAPSULE, DELAYED RELEASEDRUG FOR FURTHER PROCESSING
-Duloxetine hydrochlorideCAPSULE, DELAYED RELEASEDRUG FOR FURTHER PROCESSING
-Fluoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Fluoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Fluoxetine hydrochlorideCAPSULEDRUG FOR FURTHER PROCESSING
-Insulin lisproCRYSTALBULK INGREDIENT
-Insulin lisproCRYSTALBULK INGREDIENT
-Raloxifene hydrochlorideTABLETDRUG FOR FURTHER PROCESSING
-TadalafilTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-TadalafilTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-TadalafilTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-TadalafilTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-TadalafilTABLETDRUG FOR FURTHER PROCESSING
-abemaciclibTABLETDRUG FOR FURTHER PROCESSING
-abemaciclibTABLETDRUG FOR FURTHER PROCESSING
-abemaciclibTABLETDRUG FOR FURTHER PROCESSING
-abemaciclibTABLETDRUG FOR FURTHER PROCESSING
-baricitinibTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-baricitinibTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-baricitinibTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-lasmiditanTABLETDRUG FOR FURTHER PROCESSING
-lasmiditanTABLETDRUG FOR FURTHER PROCESSING
-orforglipronCAPSULEDRUG FOR FURTHER PROCESSING
-orforglipronCAPSULEDRUG FOR FURTHER PROCESSING
-orforglipronCAPSULEDRUG FOR FURTHER PROCESSING
-orforglipronCAPSULEDRUG FOR FURTHER PROCESSING
-orforglipronCAPSULEDRUG FOR FURTHER PROCESSING
-orforglipronCAPSULEDRUG FOR FURTHER PROCESSING
-orforglipronTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-orforglipronTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-orforglipronTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-orforglipronTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-orforglipronTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-orforglipronTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.